Company news
Cosciens Biopharma Inc. (TSX:CSCI) news
Cosciens Biopharma Inc. news releases on 6ix. Latest, Nov 26, 2012: Aeterna Zentaris: Final Phase 2 Data for Perifosine in Lymphomas to be Presented…
Press releases — page 4
Aeterna Zentaris: Final Phase 2 Data for Perifosine in Lymphomas to be Presented at Upcoming ASH Meeting
November 26, 2012
Aeterna Zentaris: Data Demonstrate that Perifosine Combined with Temsirolimus Was Well Tolerated in Phase 1 Trial in Malignant Glioma
November 19, 2012
Aeterna Zentaris Reports Third Quarter 2012 Financial and Operating Results
November 13, 2012
Aeterna Zentaris Announces Initiation of Phase 2 Portion of Phase 1/2 Trial with AEZS-108 in Prostate Cancer
November 12, 2012
Aeterna Zentaris Presents Proof-of-Concept for Disorazol Z Cytotoxic Conjugates, such as AEZS-125, in Ovarian Cancer Mouse Model at ENA Symposium
November 8, 2012
Aeterna Zentaris to Announce Third Quarter 2012 Financial and Operating Results on November 13, 2012
November 7, 2012
Aeterna Zentaris to Present Proof of Concept for Disorazol Z Cytotoxic Conjugates such as AEZS-125 in Ovarian Cancer Mouse Model at Upcoming ENA Symposium
November 1, 2012
Aeterna Zentaris Regains Compliance with NASDAQ $1.00 Minimum Bid Price Rule
October 22, 2012
Aeterna Zentaris: Phase 3 Results for AEZS-130 in AGHD Presented at GRS and IGF Society Congress
October 18, 2012
Aeterna Zentaris Announces Closing of US$16.5 Million Public Offering of Common Shares and Warrants
October 17, 2012
Aeterna Zentaris Announces Pricing of US$16.5 Million Public Offering of Common Shares and Warrants
October 12, 2012
Aeterna Zentaris: Phase 3 Results for AEZS-130 in AGHD to be Presented at Upcoming GRS and IGF Society Congress
October 10, 2012
Aeterna Zentaris Announces Share Consolidation to Regain NASDAQ Compliance
October 3, 2012
Aeterna Zentaris Presented Poster on Oral Prostate Cancer Vaccine, AEZS-120, at International Urology Conference in Japan
October 2, 2012
Aeterna Zentaris Provides Update on NDA Filing for AEZS-130 as Diagnostic Test for Adult Growth Hormone Deficiency
September 26, 2012
Aeterna Zentaris Granted Patent by European Patent Office for AEZS-130 in Growth Hormone Deficiency Diagnosis
September 25, 2012
Aeterna Zentaris to Present Poster on Oral Prostate Cancer Vaccine Candidate, AEZS-120, at Upcoming International Urology Conference in Japan
September 20, 2012
Aeterna Zentaris to Present at Rodman & Renshaw 14th Annual Global Investment Conference in New York
September 5, 2012
Aeterna Zentaris to Present at Stifel Nicolaus Healthcare Conference in Boston
August 29, 2012
Aeterna Zentaris Announces First Patient Recruited for Phase 2A Trial in Cancer Cachexia with AEZS-130
August 28, 2012
Aeterna Zentaris Reports Second Quarter 2012 Financial and Operating Results
August 14, 2012
Aeterna Zentaris to Present Preclinical Data for PI3K/Erk 1/2 Inhibitor, AEZS-136, at ACS National Meeting
August 13, 2012
Aeterna Zentaris to Announce Second Quarter 2012 Financial and Operating Results on August 14, 2012
August 8, 2012
Aeterna Zentaris Granted Patent in the U.S. for AEZS-130 as Diagnostic Test for Adult Growth Hormone Deficiency
August 7, 2012
Aeterna Zentaris: Preclinical Data for AEZS-108 in Bladder Cancer Published Online in Oncotarget
July 26, 2012
Aeterna Zentaris Requests Fast Track Designation from the FDA for AEZS-130 as Diagnostic Test for Adult Growth Hormone Deficiency
July 24, 2012
Aeterna Zentaris to Present at 7th Annual JMP Securities Healthcare Conference in New York
July 5, 2012
Aeterna Zentaris: Partner Yakult Initiates Phase 1 Trial in Multiple Myeloma with Perifosine in Japan
June 28, 2012
Aeterna Zentaris: Final Phase 3 Results for AEZS-130 in Adult Growth Hormone Deficiency Presented at ENDO Meeting
June 26, 2012
Aeterna Zentaris: Phase 1 Results Show Perifosine's Activity Against Neuroblastoma
June 21, 2012
Aeterna Zentaris Learns of Class Action Lawsuits Filed and Denies Allegations
June 19, 2012
Aeterna Zentaris: Phase 2 Data for Perifosine as Monotherapy for Renal Cell Carcinoma Published in June Issue of Cancer
June 18, 2012
Aeterna Zentaris: Phase 3 Results for AEZS-130 in AGHD to be Presented at Upcoming ENDO Meeting
June 14, 2012
Aeterna Zentaris: Poster on Phase 1 Results for Perifosine in Neuroblastoma to be Presented at Upcoming Neuroblastoma Research Conference in Toronto
June 13, 2012
Aeterna Zentaris: Phase 1 Data for Perifosine in Multiple Myeloma Published in the British Journal of Haematology
June 5, 2012
Aeterna Zentaris: Phase 3 Data for Perifosine in Colorectal Cancer Presented at ASCO Meeting
June 4, 2012
Aeterna Zentaris: Article on Perifosine as Potential Novel Approach to the Treatment of Mesothelioma Published in Plos One
May 31, 2012
Aeterna Zentaris Reports First Quarter 2012 Financial and Operating Results
May 9, 2012
Aeterna Zentaris Regains North American Rights for Perifosine from Keryx
May 7, 2012
Aeterna Zentaris to Present at 11th Annual JMP Securities Research Conference in San Francisco
May 3, 2012
Aeterna Zentaris to Announce First Quarter 2012 Financial and Operating Results and Hold Annual Shareholders Meeting on May 9, 2012
May 1, 2012
Aeterna Zentaris Presents Preclinical Data for Its Anti-Cancer PI3K/ Erk 1/2 Inhibitor, AEZS-136, at AACR Meeting
April 3, 2012
Aeterna Zentaris Announces Top-Line Data from the Perifosine Phase 3 Trial in Refractory Advanced Colorectal Cancer
April 2, 2012
Aeterna Zentaris to Present at Needham Healthcare Conference in New York
March 29, 2012
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2011 Financial and Operating Results
March 27, 2012
Aeterna Zentaris to Present Preclinical Data for Anticancer Compounds Perifosine and AEZS-136 at Upcoming AACR Meeting
March 26, 2012
Aeterna Zentaris to Announce Fourth Quarter and Full Year 2011 Financial and Operating Results on March 27, 2012
March 20, 2012
Michael E. DeBakey VA Medical Center Initiates Phase 2A Trial in Cancer Cachexia with Aeterna Zentaris' Ghrelin Agonist, AEZS-130
March 8, 2012
Aeterna Zentaris to Present at Cowen and Company 32nd Annual Health Care Conference in Boston
February 29, 2012
Aeterna Zentaris to Present at BIO CEO Investor and RBC Capital Markets Global Healthcare Conferences in New York
February 7, 2012